Targeting HRAS in head and neck cancer: Lessons from the past and future promise Review
| Authors: | Desilets, A.; Ho, A. L. |
| Review Title: | Targeting HRAS in head and neck cancer: Lessons from the past and future promise |
| Abstract: | HRAS mutations define a unique biologic subset of head and neck squamous cell carcinoma. Oncogenic HRAS is uniquely dependent on posttranslational farnesylation for membrane localization and activation of downstream signaling. Tipifarnib, a farnesyltransferase inhibitor, demonstrated encouraging antitumor activity for HRAS mutant head and neck squamous cell carcinoma and modest activity for HRAS mutant salivary gland cancer. New combination strategies to circumvent intrinsic and acquired resistance to TFIs are being investigated. © Wolters Kluwer Health, Inc. All rights reserved. |
| Keywords: | gene mutation; genetics; mutation; review; drug targeting; antineoplastic activity; cell line, tumor; phosphatidylinositol 3 kinase; cancer therapy; oncogene h ras; head and neck cancer; head and neck neoplasms; tumor cell line; protein farnesyltransferase inhibitor; tipifarnib; ras protein; protein p21; proto-oncogene proteins p21(ras); head and neck tumor; biological product; biological products; head and neck squamous cell carcinoma; molecularly targeted therapy; hras; farnesyltranstransferase; farnesyltransferase inhibitors; combination drug therapy; mapk signaling; humans; human; farnesyl trans transferase; hras protein, human; squamous cell carcinoma of head and neck |
| Journal Title: | The Cancer Journal |
| Volume: | 28 |
| Issue: | 5 |
| ISSN: | 1528-9117 |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2022-09-01 |
| Start Page: | 363 |
| End Page: | 368 |
| Language: | English |
| DOI: | 10.1097/ppo.0000000000000616 |
| PUBMED: | 36165724 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Antoine Desilets's affiliation is listed incorrectly as MSK in the publication -- Export Date: 1 November 2022 -- Source: Scopus |
